Literature DB >> 8911635

Pharmacological effects of oximes: how relevant are they?

H P van Helden1, R W Busker, B P Melchers, P L Bruijnzeel.   

Abstract

The increased international concern about the threat of military and terroristic use of nerve agents, prompted us to critically consider the expected value of the currently available oxime treatment of nerve agent poisoning. Although oximes have been designed to reactivate the inhibited acetylcholinesterase (AChE), clinical experience has indicated that they are not always very effective as reactivators and at this very moment none of them can be regarded as a broad-spectrum antidote. In spite of this drawback, oximes are worth further investigating, since recent data derived from soman or tabun lethally intoxicated non-human primates suggest that the oxime HI-6 may exert a pharmacological effect that is not related to reactivation of inhibited AChE, but still leads to survival. This pharmacological effect causes recovery of neuronal transmission in the respiratory centres of the brain and recovery of neuromuscular transmission in the diaphragm. These findings have stimulated research to reveal the pharmacological basis of these effects in order to find drugs which could be more effective and less toxic than the available oximes. Since cholinergic drugs were able to exert this effect, a new concept for further treatment is suggested: maintenance of neuronal transmission in spite of continued AChE-inhibition by pharmacological manipulation of the cholinergic receptor. This should renew interest in the diverse pharmacological effects of oximes to reach a more effective treatment in the future.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8911635     DOI: 10.1007/s002040050340

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  8 in total

1.  Methylacridinium and its cholinergic properties.

Authors:  Ondrej Soukup; Jan Proska; Jiri Binder; Jana Zdarova Karasova; Gunnar Tobin; Daniel Jun; Jan Marek; Kamil Musílek; Josef Fusek; Kamil Kuca
Journal:  Neurotox Res       Date:  2009-06-30       Impact factor: 3.911

2.  Intrathecal delivery of fluorescent labeled butyrylcholinesterase to the brains of butyrylcholinesterase knock-out mice: visualization and quantification of enzyme distribution in the brain.

Authors:  Noel D Johnson; Ellen G Duysen; Oksana Lockridge
Journal:  Neurotoxicology       Date:  2009-03-20       Impact factor: 4.294

3.  Tiapride pre-treatment in acute exposure to paraoxon: comparison of effects of administration at different points-in-time in rats.

Authors:  G A Petroianu; M Y Hasan; S M Nurulain; K Arafat; M Shafiullah; R Sheen
Journal:  Mol Cell Biochem       Date:  2006-02-15       Impact factor: 3.396

4.  (E)-1-(Pyridin-2-yl)ethanone O-acryloyloxime.

Authors:  Mariusz Mojzych; Zbigniew Karczmarzyk; Andrzej Fruziński
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-03-05

Review 5.  Organophosphorus compounds and oximes: a critical review.

Authors:  Franz Worek; Horst Thiermann; Timo Wille
Journal:  Arch Toxicol       Date:  2020-06-06       Impact factor: 5.153

6.  Molecular Modeling and In Vitro Studies of a Neutral Oxime as a Potential Reactivator for Acetylcholinesterase Inhibited by Paraoxon.

Authors:  Reuel L de Paula; Joyce S F D de Almeida; Samir F A Cavalcante; Arlan S Gonçalves; Alessandro B C Simas; Tanos C C Franca; Martin Valis; Kamil Kuca; Eugenie Nepovimova; José M Granjeiro
Journal:  Molecules       Date:  2018-11-12       Impact factor: 4.411

7.  Health aspects of organophosphorous pesticides in asian countries.

Authors:  M Balali-Mood; K Balali-Mood; M Moodi; B Balali-Mood
Journal:  Iran J Public Health       Date:  2012-10-01       Impact factor: 1.429

Review 8.  Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment.

Authors:  Ondrej Soukup; Michael Winder; Uday Kumar Killi; Vladimir Wsol; Daniel Jun; Kamil Kuca; Gunnar Tobin
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.